Read the Article and Objectives
The knowledge check is based on the assigned article. Use Thompson policy, provider orders, pharmacy guidance, and unit escalation pathways for actual patient care.
Learning objectives
After completing this activity, the bedside RN should be able to:
- Recognize common anticoagulant classes and connect them with the reversal agents discussed in the article.
- Identify criteria that make bleeding major, critical-site, or life-threatening enough to require urgent escalation.
- Describe bedside nursing priorities when reversal is being considered, including last-dose history, focused assessment, labs, access, monitoring, and protocol activation.
- Explain key safety concerns with reversal therapy, including thrombotic risk, volume burden, and infusion or hypersensitivity reactions.
Bedside RN Quick Reference
This is the practical lens for med-surg and ICU nurses. The nurse does not independently choose a reversal agent, but the nurse can make the team faster and safer by surfacing the right information.
| Anticoagulant or situation | Article-based reversal anchor | Bedside RN focus |
|---|---|---|
| Warfarin / vitamin K antagonist | Vitamin K and 4-factor PCC are recommended for serious bleeding. FFP may be considered if PCC is unavailable. | Report INR and last dose, maintain IV access, prepare for ordered blood product or factor therapy, and monitor for worsening bleeding or thrombosis. |
| Heparin or enoxaparin | Protamine reverses heparin and partially reverses LMWH. Dosing depends heavily on timing and amount of the last dose. | Clarify infusion stop time or injection time, monitor for hypotension, bradycardia, flushing, or anaphylaxis, and continue bleeding assessment. |
| Dabigatran | Idarucizumab is the specific reversal agent. The article describes a 5 g IV dose supplied as two 2.5 g doses. | Confirm medication history, renal context when available, active bleeding status, labs ordered by the team, and response after reversal. |
| Factor Xa inhibitors such as apixaban or rivaroxaban | Andexanet alfa is discussed for apixaban and rivaroxaban reversal. PCC or activated PCC may be used depending on availability and clinical scenario. | Get the last dose time and dose if possible, watch for neurologic or hemodynamic change, and monitor for thrombotic events after procoagulant therapy. |
| Massive or uncontrolled bleeding | Nonpharmacologic bleeding control, resuscitation, massive transfusion protocol, and calcium replacement may be part of the response. | Escalate early, trend vital signs and blood loss, prepare access and labs, follow MTP workflow, and anticipate calcium monitoring/repletion per orders. |
Major bleed clues
The article highlights critical-site bleeding, hemodynamic instability, a hemoglobin drop of at least 2 g/dL, or transfusion of at least 2 units of packed red blood cells as major bleed criteria.
Stability matters
Once bleeding appears controlled and hemodynamics improve, the team reassesses whether anticoagulation is still indicated and whether restarting is appropriate.
Knowledge Check
Answer eight focused questions. A score of 80% or higher reports as passed in the LMS.
Complete
Review the score. A passing score is required before the activity can be finished.
Activity summary
Complete the knowledge check to record your score.